- Home
- BIAF vs ERNA Comparison
BIAF vs ERNA Comparison
Compare BIAF & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- ERNA
- Stock Information
- Founded
- BIAF 2014
- ERNA 2018
- Country
- BIAF United States
- ERNA United States
- Employees
- BIAF N/A
- ERNA N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- ERNA Health Care
- Exchange
- BIAF Nasdaq
- ERNA Nasdaq
- Market Cap
- BIAF 12.2M
- ERNA 14.5M
- IPO Year
- BIAF 2022
- ERNA N/A
- Fundamental
- Price
- BIAF $0.49
- ERNA $0.19
- Analyst Decision
- BIAF Hold
- ERNA
- Analyst Count
- BIAF 1
- ERNA 0
- Target Price
- BIAF N/A
- ERNA N/A
- AVG Volume (30 Days)
- BIAF 28.5M
- ERNA 213.9K
- Earning Date
- BIAF 05-14-2025
- ERNA 05-13-2025
- Dividend Yield
- BIAF N/A
- ERNA N/A
- EPS Growth
- BIAF N/A
- ERNA N/A
- EPS
- BIAF N/A
- ERNA N/A
- Revenue
- BIAF $9,362,022.00
- ERNA $582,000.00
- Revenue This Year
- BIAF N/A
- ERNA N/A
- Revenue Next Year
- BIAF $19.99
- ERNA N/A
- P/E Ratio
- BIAF N/A
- ERNA N/A
- Revenue Growth
- BIAF 269.68
- ERNA 755.88
- 52 Week Low
- BIAF $0.24
- ERNA $0.15
- 52 Week High
- BIAF $3.16
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- BIAF 48.21
- ERNA 44.20
- Support Level
- BIAF $0.46
- ERNA $0.17
- Resistance Level
- BIAF $0.58
- ERNA $0.21
- Average True Range (ATR)
- BIAF 0.11
- ERNA 0.02
- MACD
- BIAF -0.01
- ERNA 0.00
- Stochastic Oscillator
- BIAF 8.65
- ERNA 73.00
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.